Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the US

6 Jun 2022

Abstract excerpt

OBJECTIVE: Persons with immune-mediated inflammatory diseases (IMIDs) are at an increased risk of herpes zoster (HZ). In 2018, the Centers for Disease Control and Prevention recommended a highly efficacious vaccine, recombinant zoster vaccine (RZV), for prevention of HZ in immunocompetent patients ≥50 years of age. This study was undertaken to estimate RZV vaccination among adults ages ≥50 years with IMIDs during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Herpesvirus Infections and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35666070
DOI: 10.1002/art.42261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the USPMID 35666070Read ↗

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune DiseasesSemantic proximity Read ↗

Efficacy and side effects of the Herpes Zoster vaccine in immunocompromised individuals – a systematic reviewSemantic proximity Read ↗

Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocolSemantic proximity Read ↗

Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year PersistenceSemantic proximity Read ↗

Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantationSemantic proximity Read ↗

Epidemiology and clinical profile of herpes zoster in the varicella vaccine era: A case series studySemantic proximity Read ↗

Unraveling the Immune Signature of Herpes Zoster: Insights Into the Pathophysiology and Human Leukocyte Antigen Risk Profile.Semantic proximity Read ↗

What does epidemiology tell us about risk factors for herpes zoster?Semantic proximity Read ↗

Sequential Data-Mining for Adverse Events After Recombinant Herpes Zoster Vaccination Using the Tree-Based Scan StatisticSemantic proximity Read ↗

Unraveling the immune signature of herpes zoster: Insights into pathophysiology and the HLA risk profileSemantic proximity Read ↗

Administering Shingles Vaccine Prior to Initiation of Biologics TherapySemantic proximity Read ↗

Immune response to an adjuvanted recombinant zoster vaccine in Japanese patients with rheumatoid arthritis receiving upadacitinib (End Zoster-J study)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.